PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma.

(2017) J. F. San-Miguel et al.   JOURNAL OF CLINICAL ONCOLOGY

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02

(2013) X. Leleu et al.   BLOOD

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

(2012) S. Kumar et al.   BLOOD

Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation

(2012) Camelia Iancu-Rubin et al.   EXPERIMENTAL HEMATOLOGY

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

(2011) M. J. Bishton et al.   BLOOD

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

(2010) C R Giver et al.   LEUKEMIA

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS